Graft-versus-host disease risk factors: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) |
Shyam Patel (talk | contribs) |
||
| Line 9: | Line 9: | ||
Risk factors for GvHD include: | Risk factors for GvHD include: | ||
*High degree of HLA disparity between host and donor cells<ref name="pmid22770714">{{cite journal| author=Rezvani AR, Storb RF| title=Prevention of graft-vs.-host disease. | journal=Expert Opin Pharmacother | year= 2012 | volume= 13 | issue= 12 | pages= 1737-50 | pmid=22770714 | doi=10.1517/14656566.2012.703652 | pmc=3509175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22770714 }} </ref> | *High degree of [[HLA]] disparity between host and donor cells<ref name="pmid22770714">{{cite journal| author=Rezvani AR, Storb RF| title=Prevention of graft-vs.-host disease. | journal=Expert Opin Pharmacother | year= 2012 | volume= 13 | issue= 12 | pages= 1737-50 | pmid=22770714 | doi=10.1517/14656566.2012.703652 | pmc=3509175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22770714 }} </ref> | ||
*Use of unrelated donors as the stem cell source<ref name="pmid22770714">{{cite journal| author=Rezvani AR, Storb RF| title=Prevention of graft-vs.-host disease. | journal=Expert Opin Pharmacother | year= 2012 | volume= 13 | issue= 12 | pages= 1737-50 | pmid=22770714 | doi=10.1517/14656566.2012.703652 | pmc=3509175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22770714 }} </ref> | *Use of unrelated donors as the stem cell source<ref name="pmid22770714">{{cite journal| author=Rezvani AR, Storb RF| title=Prevention of graft-vs.-host disease. | journal=Expert Opin Pharmacother | year= 2012 | volume= 13 | issue= 12 | pages= 1737-50 | pmid=22770714 | doi=10.1517/14656566.2012.703652 | pmc=3509175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22770714 }} </ref> | ||
*Total body irradiation as the conditioning regimen prior to transplant<ref name="pmid22770714">{{cite journal| author=Rezvani AR, Storb RF| title=Prevention of graft-vs.-host disease. | journal=Expert Opin Pharmacother | year= 2012 | volume= 13 | issue= 12 | pages= 1737-50 | pmid=22770714 | doi=10.1517/14656566.2012.703652 | pmc=3509175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22770714 }} </ref> | *[[Total body irradiation]] as the conditioning regimen prior to transplant<ref name="pmid22770714">{{cite journal| author=Rezvani AR, Storb RF| title=Prevention of graft-vs.-host disease. | journal=Expert Opin Pharmacother | year= 2012 | volume= 13 | issue= 12 | pages= 1737-50 | pmid=22770714 | doi=10.1517/14656566.2012.703652 | pmc=3509175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22770714 }} </ref> | ||
*Prior acute GvHD<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | *Prior acute GvHD<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | ||
*Use of peripheral blood stem cells<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | *Use of peripheral blood stem cells<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | ||
*Use of a T | *Use of a [[T cell]] replete graft<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | ||
*Viral infection, since this can contribute to immune activation<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | *Viral infection, since this can contribute to immune activation<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | ||
*Male host<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | *Male host<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | ||
| Line 22: | Line 22: | ||
Protective risk factors include: | Protective risk factors include: | ||
*High degree of HLA concordance between the host and donor | *High degree of [[HLA]] concordance between the host and donor | ||
*Use of umbilical cord blood as the donor source (given decreased number of donor T cells) | *Use of [[umbilical cord blood]] as the donor source (given decreased number of donor T cells) | ||
==References== | ==References== | ||
Revision as of 21:38, 21 June 2017
|
Graft-versus-host disease |
|
Differentiating Graft-versus-host disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Graft-versus-host disease risk factors On the Web |
|
American Roentgen Ray Society Images of Graft-versus-host disease risk factors |
|
Risk calculators and risk factors for Graft-versus-host disease risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
The major risk factor for GvHD is disparity in HLA alleles between the recipient and host.
Risk Factors
Risk factors for GvHD include:
- High degree of HLA disparity between host and donor cells[1]
- Use of unrelated donors as the stem cell source[1]
- Total body irradiation as the conditioning regimen prior to transplant[1]
- Prior acute GvHD[2]
- Use of peripheral blood stem cells[2]
- Use of a T cell replete graft[2]
- Viral infection, since this can contribute to immune activation[2]
- Male host[2]
- Multiparous female donor[2]
Protective risk factors include:
- High degree of HLA concordance between the host and donor
- Use of umbilical cord blood as the donor source (given decreased number of donor T cells)
References
- ↑ 1.0 1.1 1.2 Rezvani AR, Storb RF (2012). "Prevention of graft-vs.-host disease". Expert Opin Pharmacother. 13 (12): 1737–50. doi:10.1517/14656566.2012.703652. PMC 3509175. PMID 22770714.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Socié G, Ritz J (2014). "Current issues in chronic graft-versus-host disease". Blood. 124 (3): 374–84. doi:10.1182/blood-2014-01-514752. PMC 4102710. PMID 24914139.